吕万良课题组在靶向性载药脂质体抗耐药性乳腺癌研究方面取得进展

中国药学(英文版) ›› 2021, Vol. 30 ›› Issue (2): 179-180.

吕万良课题组在靶向性载药脂质体抗耐药性乳腺癌研究方面取得进展

北京大学药学院科研与国重办公室

北京大学药学院科研与国重办公室

收稿日期:2021-02-22 修回日期:2021-02-22 接受日期:2021-02-22 出版日期:2021-02-28 发布日期:2021-02-27

The research group of Professor Wanliang Lv has made progress in the study of targeted functional liposomes against drug-resistant breast cancer

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2021-02-22 Revised:2021-02-22 Accepted:2021-02-22 Online:2021-02-28 Published:2021-02-27

摘要/Abstract

摘要：

1月31日, 北京大学药学院天然药物及仿生药物国家重点实验室吕万良课题组在国际著名学术期刊《Small》在线发表了题为“Nanostructure of functional larotaxel liposomes decorated with guanine-rich quadruplex nucleotide-lipid derivative for treatment of resistant breast cancer”的研究工作。

Supporting:

北京大学药学院科研与国重办公室. 吕万良课题组在靶向性载药脂质体抗耐药性乳腺癌研究方面取得进展[J]. 中国药学(英文版), 2021, 30(2): 179-180.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The research group of Professor Wanliang Lv has made progress in the study of targeted functional liposomes against drug-resistant breast cancer[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(2): 179-180.